Kantonsspital Baselland
Kantonsspital Baselland
Liestal, Switzerland12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Not stated | 2026-09-30 | NCT04579367 | |
| DESTINY Breast Respond HER2-(Ultra)Low Europe | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-08-19 | NCT05945732 | |
| Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-08-17 | NCT06358573 | |
| Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-06-23 | NCT05555732 | |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-04-30 | NCT04608318 | |
| LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Not applicable | 2026-03-30 | NCT06090162 | |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Peritoneal Diseases, Urogenital Diseases, Urogenital Neoplasms, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, ovarian endometrioid adenocarcinoma, peritoneal neoplasm | Recruiting | Phase 3 | 2025-09-29 | NCT04111978 | |
| Swiss Primary Sclerosing Cholangitis Cohort Study | Cholangitis, Sclerosing, Digestive System Diseases, bile duct disorder, biliary tract disorder, cholangitis, primary sclerosing cholangitis | Recruiting | Not stated | 2025-08-19 | NCT03146936 | |
| Swiss Autoimmune Hepatitis Cohort Study | Digestive System Diseases, Hepatitis, Chronic, autoimmune disease, autoimmune hepatitis, hepatitis, immune system disorder, liver disorder | Recruiting | Not stated | 2025-08-18 | NCT03146884 | |
| Swiss Primary Biliary Cholangitis Cohort Study | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Not stated | 2025-08-17 | NCT03146910 | |
| Urinary Prostaglandin as a Potential Predictive Marker for Thiazide-induced Hyponatremia | Hyponatremia, Nutritional and Metabolic Diseases, Water-Electrolyte Imbalance, metabolic disease | Recruiting | Not stated | 2025-07-01 | NCT05542056 | |
| Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors | Advanced Solid Tumor | Recruiting | Phase 4 | 2024-12-27 | NCT06408688 |